

CAU 15+2

Docket No.: PF-0527-1 DIV

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, Washington, D.C. 20231

on 11-15-00By: Nancy RamosPrinted: NANCY RAMOS

RECEIVED

NOV 24 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title: PROSTATE GROWTH-ASSOCIATED MEMBRANE PROTEINS

Serial No.: 09/397,558

Filing Date: September 16, 1999

Examiner: Harris, A.

Group Art Unit: 1642

TECH CENTER 1600/2932

Commissioner for Patents
Box Non-Fee Amendment
Washington, D.C. 20231

AMENDMENT TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard;
2. Amendment Transmittal Fee Sheet (1pg., in duplicate);
3. Response to Office Action (9 pp., in duplicate);
4. Notice of Limited Recognition (1pg).

The fee has been calculated as shown below.

Claims	Claims After Amendment	-	Claims Previously Paid For	=	Present Extra	Other Than Small Entity Rate Fee	Additional Fee(s)
Total Claims	19	-	20	=		\$18	\$0
Indep. Claims	3	-	3	=		\$80	\$0
___ First Presentation of Multiple Dependent Claim						+\$270	\$0
TOTAL							\$ 0.00

X No additional fee is required.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit
overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 15 NOV 2000.Adam Warwick Bell, D.Phil.

Reg. No. 43,490

Direct Dial Telephone: (650) 621-7542

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886




**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Terence Lo is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of Incyte Pharmaceuticals, Inc. to prepare and prosecute patent applications wherein Incyte Pharmaceuticals, Inc. is the assignee of record of the entire interest. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Terence Lo ceases to lawfully reside in the United States, (ii) Terence Lo's employment with Incyte Pharmaceuticals, Inc. ceases or is terminated, or (iii) Terence Lo ceases to remain or reside in the United States on a TN visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

Expires: November 19, 2000



Harry I. Moatz, Director
Office of Enrollment and Discipline